Antiviral chemistry & chemotherapy

Keyphrases

Publications

volume 31, 2023

Norbert J Roberts
The continuing need for therapeutic agents for respiratory syncytial virus infection. Antiviral chemistry & chemotherapy 31 (2023)
Erik De Clercq
The development of BVDU: An odyssey. Antiviral chemistry & chemotherapy 31 (2023)
Erik De Clercq
The development of BVDU: An odyssey. Antiviral chemistry & chemotherapy 31 (2023)
Erik De Clercq
The development of BVDU: An odyssey. Antiviral chemistry & chemotherapy 31 (2023)

volume 30, 2022

Jureeporn Chuerduangphui, Thawaree Nukpook, Chamsai Pientong, Chantana Aromdee, Supawadee Suebsasana, Watcharee Khunkitti, Charinya So-In, Kanisara Proyrungroj, Tipaya Ekalaksananan
Activity of 3,19-isopropylidinyl andrographolide against herpes simplex virus type 1 in an animal model. Antiviral chemistry & chemotherapy 30 (2022)
Hranush Avagyan, Anaida Mirzoyan, Ferdinand Mirzoyan, Roza Izmailyan, Sona Hakobyan, Henry Voskanyan, Zara Semerjyan, Aida Avetisyan, Hranush Arzumanyan, Elena Karalova, Liana Abroyan, Lina Hakobyan, Nane Bayramyan, Nazeli Gevorgyan, Alexander Karalyan, Zaven A Karalyan
New composition of tungsten has a broad range of antiviral activity. Antiviral chemistry & chemotherapy 30 (2022)
Andrea Brancale, Kara Carter, Leen Delang, Jerome Deval, David Durantel, Brian G Gentry, Robert Jordan, Justin G Julander, Michael K Lo, Maria-Jesús Pérez-Pérez, Luis M Schang, Katherine L Seley-Radtke, Pei-Yong Shi, Subhash G Vasudevan, Richard J Whitley, Jessica R Spengler
Meeting report: 34th international conference on antiviral research. Antiviral chemistry & chemotherapy 30 (2022)
Robert G Gish, Tarik Asselah, Katherine Squires, Douglas Mayers
Active site polymerase inhibitor nucleotides (ASPINs): Potential agents for chronic HBV cure regimens. Antiviral chemistry & chemotherapy 30 (2022)
Robert A Newman, Christopher C L Chase, Jose R Matos, Karim Abdelsalam, Robin Buterbaugh, Sonja Van Holland, Hadia Abdelaal, Amelia Woolum, K Jagannadha Sastry
Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health. Antiviral chemistry & chemotherapy 30 (2022)
Erik De Clercq
Reflections on the Rega Institute for Medical Research, at the fiftieth anniversary of the Rega Stichting vzw (Rega Instituut vzw, Rega Foundation). Antiviral chemistry & chemotherapy 30 (2022)

volume 29, 2021

M E Lewis, B Jubb, P Simpson, A Lopatukhin, D Kireev, M Bobkova, Charles Craig, E van der Ryst, M Westby, S L Butler
Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc. Antiviral chemistry & chemotherapy 29 (2021)
M E Lewis, P Simpson, J Mori, B Jubb, J Sullivan, L McFadyen, E van der Ryst, Charles Craig, D L Robertson, M Westby
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens. Antiviral chemistry & chemotherapy 29 (2021)
Aurora Salamanca, Paula Almodóvar, Irene Jarama, Daniel González-Hedström, Marin Prodanov, Antonio Manuel Inarejos-García
Anti-influenza virus activity of the elenolic acid rich olive leaf (Olea europaea L.) extract Isenolic®. Antiviral chemistry & chemotherapy 29 (2021)
Jana Van Dycke, Jasper Rymenants, Johan Neyts, Joana Rocha-Pereira
Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Identification of active compounds. Antiviral chemistry & chemotherapy 29 (2021)
Gregory Mathez, Valeria Cagno
Clinical severe acute respiratory syndrome coronavirus 2 isolation and antiviral testing. Antiviral chemistry & chemotherapy 29 (2021)
Gang Zhang, Xing Huang
Killing HIV-infected resting central memory CD4+ T cells by targeting inhibitor of apoptosis proteins-inhibited autophagy. Antiviral chemistry & chemotherapy 29 (2021)
Wenxiao Zheng, Leonardo D'Aiuto, Matthew J Demers, Vaishali Muralidaran, Joel A Wood, Maribeth Wesesky, Ansuman Chattopadhyay, Vishwajit L Nimgaonkar
Insights into bioinformatic approaches for repurposing compounds as anti-viral drugs. Antiviral chemistry & chemotherapy 29 (2021)
Jana Van Dycke, Jasper Rymenants, Johan Neyts, Joana Rocha-Pereira
Assessment of the anti-norovirus activity in cell culture using the mouse norovirus: Early mechanistic studies. Antiviral chemistry & chemotherapy 29 (2021)
Sebastiaan Ter Horst, Winston Chiu, Johan Neyts, Joana Rocha-Pereira
Screening and in vitro antiviral assessment of small molecules against fluorescent protein-expressing Bunyamwera virus in a cell-based assay using high-content imaging. Antiviral chemistry & chemotherapy 29 (2021)

volume 28, 2021

Katherine L Seley-Radtke
Small molecule antivirals - Still our best hope for a cure. Antiviral chemistry & chemotherapy 28 (2021)
Evgenia V Dueva, Ksenia K Tuchynskaya, Liubov I Kozlovskaya, Dmitry I Osolodkin, Kseniya N Sedenkova, Elena B Averina, Vladimir A Palyulin, Galina G Karganova
Spectrum of antiviral activity of 4-aminopyrimidine N-oxides against a broad panel of tick-borne encephalitis virus strains. Antiviral chemistry & chemotherapy 28 (2021)
Ali Karimi, Mohammad Taghi Moradi, Mohammad Rabiei, Somayeh Alidadi
In vitro anti-adenoviral activities of ethanol extract, fractions, and main phenolic compounds of pomegranate (Punica granatum L.) peel. Antiviral chemistry & chemotherapy 28 (2021)
Venkatraman Siddharthan, Hong Wang, Alexandre Lr de Oliveira, Xin Dai, John D Morrey
Memantine treatment reduces the incidence of flaccid paralysis in a zika virus mouse model of temporary paralysis with similarities to Guillain-Barré syndrome. Antiviral chemistry & chemotherapy 28 (2021)
Kohsuke Nakagawara, Hironori Hayashi, Kumi Kawaji, Mina Sasano, Eiichi N Kodama
Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir. Antiviral chemistry & chemotherapy 28 (2021)
Elena Margret Thornhill, Jessica Salpor, David Verhoeven
Respiratory syntycial virus: Current treatment strategies and vaccine approaches. Antiviral chemistry & chemotherapy 28 (2021)
Sun Hee Lee, Hyun Phil Shin, Joung Il Lee
Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment. Antiviral chemistry & chemotherapy 28 (2021)
Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antiviral chemistry & chemotherapy 28 (2021)
Oludare M Ogunyemi, Gideon Ampoma Gyebi, Abdo A Elfiky, Saheed O Afolabi, Olalekan Bukunmi Ogunro, Adegbenro P Adegunloye, Ibrahim M Ibrahim
Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective. Antiviral chemistry & chemotherapy 28 (2021)
Wassim Chehadeh, Osama Albaksami, Shaikhah Al-Shammari
Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting. Antiviral chemistry & chemotherapy 28 (2021)

volume 28, 2020

Lawrence R Bernstein, Leike Zhang
Gallium maltolate has in vitro antiviral activity against SARS-CoV-2 and is a potential treatment for COVID-19. Antiviral chemistry & chemotherapy 28 (2020)
Dimitri Poddighe, Mohamad Aljofan
Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. Antiviral chemistry & chemotherapy 28 (2020)
Petar Grozdanov, Marie-Line Joffret, Adelina Stoyanova, Patsy Polston, Emna Achouri, Ivanka Nikolova, Francis Delpeyroux, Angel S Galabov
Genome analysis of coxsackievirus B1 isolates during the consecutive alternating administration course of triple antiviral combination in newborn mice. Antiviral chemistry & chemotherapy 28 (2020)
Johanna Huchting
Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections. Antiviral chemistry & chemotherapy 28 (2020)

volume 27, 2019

Jennifer C Becker, Sharon J Tollefson, David Weaver, John V Williams
A medium-throughput screen for inhibitors of human metapneumovirus. Antiviral chemistry & chemotherapy 27 (2019)
Francesco Di Palma, Gian Luca Daino, Venkata Krishnan Ramaswamy, Angela Corona, Aldo Frau, Elisa Fanunza, Attilio V Vargiu, Enzo Tramontano, Paolo Ruggerone
Relevance of Ebola virus VP35 homo-dimerization on the type I interferon cascade inhibition. Antiviral chemistry & chemotherapy 27 (2019)
Erik De Clercq
Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. Antiviral chemistry & chemotherapy 27 (2019)
Lucie Čechová, Milan Dejmek, Ondřej Baszczyňski, David Šaman, Liping Gao, Eric Hu, George Stepan, Petr Jansa, Zlatko Janeba, Petr Šimon
Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors. Antiviral chemistry & chemotherapy 27 (2019)
Becky Jubb, Marilyn Lewis, Lynn McFadyen, Paul Simpson, Julie Mori, Phylinda Chan, Barry Weatherley, Elna van der Ryst, Mike Westby, Charles Craig
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials. Antiviral chemistry & chemotherapy 27 (2019)

volume 26, 2019

Wolfgang Hg Laux, Stéphane Priet, Karine Alvarez, Suzanne Peyrottes, Christian Périgaud
Synthesis and substrate properties towards HIV-1 reverse transcriptase of new diphosphate analogues of 9-[(2-phosphonomethoxy)ethyl]adenine. Antiviral chemistry & chemotherapy 26 (2019)
Luděk Eyer, Radim Nencka, Erik de Clercq, Katherine Seley-Radtke, Daniel Růžek
Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses. Antiviral chemistry & chemotherapy 26 (2019)
Ashwaq A Abdullah, Rasedee Abdullah, Zeenathul A Nazariah, Krishnan N Balakrishnan, Faez Firdaus J Abdullah, Jamilu Abubakar Bala, Mohd-Azmi Mohd-Lila
Cyclophilin A as a target in the treatment of cytomegalovirus infections. Antiviral chemistry & chemotherapy 26 (2019)
Cyril B Dousson
Current and future use of nucleo(s)tide prodrugs in the treatment of hepatitis C virus infection. Antiviral chemistry & chemotherapy 26 (2019)
M S Boukhvalova, K C Yim, Jcg Blanco
Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus. Antiviral chemistry & chemotherapy 26 (2019)
Katherine L Seley-Radtke
Flexibility-Not just for yoga anymore! Antiviral chemistry & chemotherapy 26 (2019)
Hui He, Merrion Buckley, Bernard Britton, Ying Mu, Kristin Warner, Santosh Kumar, Theodore J Cory
Polarized macrophage subsets differentially express the drug efflux transporters MRP1 and BCRP, resulting in altered HIV production. Antiviral chemistry & chemotherapy 26 (2019)
Joy Y Feng
Addressing the selectivity and toxicity of antiviral nucleosides. Antiviral chemistry & chemotherapy 26 (2019)
Magdalena Slusarczyk, Michaela Serpi, Fabrizio Pertusati
Phosphoramidates and phosphonamidates (ProTides) with antiviral activity. Antiviral chemistry & chemotherapy 26 (2019)
Ondřej Baszczyňski, Martin Maxmilian Kaiser, Michal Česnek, Petra Břehová, Petr Jansa, Eliška Procházková, Martin Dračínský, Robert Snoeck, Graciela Andrei, Zlatko Janeba
Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus. Antiviral chemistry & chemotherapy 26 (2019)
David Boltz, Xinjian Peng, Miguel Muzzio, Pradyot Dash, Paul G Thomas, Victor Margitich
Activity of enisamium, an isonicotinic acid derivative, against influenza viruses in differentiated normal human bronchial epithelial cells. Antiviral chemistry & chemotherapy 26 (2019)
Valeria Famiglini, Romano Silvestri
Indolylarylsulfones, a fascinating story of highly potent human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors. Antiviral chemistry & chemotherapy 26 (2019)